This content is protected against AI scraping.
A national drug-testing advocacy group and a pharmaceutical company are asking a federal appeals court to temporarily block the Trump administration’s move to reclassify medical cannabis from Schedule I to Schedule III. They argue the change was made improperly and should be paused while their lawsuit challenging the policy moves forward.
In their filing, the groups say the rescheduling process skipped required rulemaking steps and ignored legal standards tied to how federal drug schedules are changed. They cite a decades-old court ruling and argue that federal agencies failed to properly follow both scientific review standards and administrative procedures when approving the shift.
The plaintiffs also argue they will suffer “irreparable harm” if the policy is allowed to take effect, pointing to financial losses for drug-testing programs and risks to their business investments. while also increasing marijuana access in ways they argue could harm public health. The federal government has until early July to respond,







